Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Cellulose acetate 1,2-benzenedicarboxylate protects against challenge with pathogenic X4 and R5 simian/human immunodeficiency virus.

Boadi T, Schneider E, Chung S, Tsai L, Gettie A, Ratterree M, Blanchard J, Neurath AR, Cheng-Mayer C.

AIDS. 2005 Oct 14;19(15):1587-94.

PMID:
16184027
2.
3.

Repetitive exposures with simian/human immunodeficiency viruses: strategy to study HIV pre-clinical interventions in non-human primates.

Kim CN, Adams DR, Bashirian S, Butera S, Folks TM, Otten RA.

J Med Primatol. 2006 Aug;35(4-5):210-6.

PMID:
16872284
4.

Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies.

Gautam R, Nishimura Y, Lee WR, Donau O, Buckler-White A, Shingai M, Sadjadpour R, Schmidt SD, LaBranche CC, Keele BF, Montefiori D, Mascola JR, Martin MA.

J Virol. 2012 Aug;86(16):8516-26. doi: 10.1128/JVI.00644-12. Epub 2012 May 30.

5.

Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs.

Harouse JM, Gettie A, Tan RC, Blanchard J, Cheng-Mayer C.

Science. 1999 Apr 30;284(5415):816-9.

6.

Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.

Kumar A, Mukherjee S, Shen J, Buch S, Li Z, Adany I, Liu Z, Zhuge W, Piatak M Jr, Lifson J, McClure H, Narayan O.

Virology. 2002 Sep 30;301(2):189-205.

7.

Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239.

Abel K, Rourke T, Lu D, Bost K, McChesney MB, Miller CJ.

J Infect Dis. 2004 Nov 1;190(9):1697-705. Epub 2004 Sep 24. Erratum in: J Infect Dis. 2005 Mar 15;191(6):1028.

8.

Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.

Someya K, Cecilia D, Ami Y, Nakasone T, Matsuo K, Burda S, Yamamoto H, Yoshino N, Kaizu M, Ando S, Okuda K, Zolla-Pazner S, Yamazaki S, Yamamoto N, Honda M.

J Virol. 2005 Feb;79(3):1452-62.

9.

Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques.

Trunova N, Tsai L, Tung S, Schneider E, Harouse J, Gettie A, Simon V, Blanchard J, Cheng-Mayer C.

Virology. 2006 Aug 15;352(1):169-77. Epub 2006 May 30.

10.

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, Burton DR.

J Virol. 2001 Sep;75(17):8340-7.

12.

Efficient repeated low-dose intravaginal infection with X4 and R5 SHIVs in rhesus macaque: implications for HIV-1 transmission in humans.

Tsai L, Trunova N, Gettie A, Mohri H, Bohm R, Saifuddin M, Cheng-Mayer C.

Virology. 2007 May 25;362(1):207-16. Epub 2007 Jan 29.

13.

Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses.

Wolinsky SM, Veazey RS, Kunstman KJ, Klasse PJ, Dufour J, Marozsan AJ, Springer MS, Moore JP.

Virology. 2004 Oct 10;328(1):19-29.

14.

In vivo analysis of a new R5 tropic SHIV generated from the highly pathogenic SHIV-KS661, a derivative of SHIV-89.6.

Matsuda K, Inaba K, Fukazawa Y, Matsuyama M, Ibuki K, Horiike M, Saito N, Hayami M, Igarashi T, Miura T.

Virology. 2010 Mar 30;399(1):134-43. doi: 10.1016/j.virol.2010.01.008. Epub 2010 Jan 27.

15.

Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.

Miyake A, Akagi T, Enose Y, Ueno M, Kawamura M, Horiuchi R, Hiraishi K, Adachi M, Serizawa T, Narayan O, Akashi M, Baba M, Hayami M.

J Med Virol. 2004 Jul;73(3):368-77.

PMID:
15170630
16.

MIV-150/zinc acetate gel inhibits cell-associated simian-human immunodeficiency virus reverse transcriptase infection in a macaque vaginal explant model.

Barnable P, Calenda G, Bonnaire T, Menon R, Levendosky K, Gettie A, Blanchard J, Cooney ML, Fernández-Romero JA, Zydowsky TM, Teleshova N.

Antimicrob Agents Chemother. 2015 Jul;59(7):3829-37. doi: 10.1128/AAC.00073-15. Epub 2015 Apr 13.

17.

Mucosal transmissibility, disease induction and coreceptor switching of R5 SHIVSF162P3N molecular clones in rhesus macaques.

Ren W, Mumbauer A, Zhuang K, Harbison C, Knight H, Westmoreland S, Gettie A, Blanchard J, Cheng-Mayer C.

Retrovirology. 2013 Jan 31;10:9. doi: 10.1186/1742-4690-10-9.

18.

Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.

Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, Rezk N, Kashuba A, Anton P, McGowan I, Shattock R.

PLoS Med. 2008 Aug 5;5(8):e157; discussion e157. doi: 10.1371/journal.pmed.0050157.

19.

DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory.

Manrique M, Micewicz E, Kozlowski PA, Wang SW, Aurora D, Wilson RL, Ghebremichael M, Mazzara G, Montefiori D, Carville A, Mansfield KG, Aldovini A.

AIDS Res Hum Retroviruses. 2008 Mar;24(3):505-19. doi: 10.1089/aid.2007.0191.

20.

Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus.

Endo Y, Igarashi T, Nishimura Y, Buckler C, Buckler-White A, Plishka R, Dimitrov DS, Martin MA.

J Virol. 2000 Aug;74(15):6935-45.

Supplemental Content

Support Center